X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Groups sound the alarm on administration’s new Part B proposal

By Nicole Longo  |    November 14, 2018
Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...   Read More

4 things you need to know about the administration’s latest Part B proposal

By Nicole Longo  |    November 5, 2018
The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....   Read More

PhRMA comments in response to request for information on competitive bidding program in Medicare Part B

By Nicole Longo  |    September 25, 2018
Yesterday, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the recent 2019 Hospital Outpatient Prospective Payment System proposed rule,...   Read More

Fact Check Friday: Getting the facts straight about negotiation in Medicare Part B

By Nicole Longo  |    August 24, 2018
Medicare Part B has been a hot topic in Washington, DC, this summer with an increasing number of conversations about how the program works. Unfortunately, a common misconception keeps popping up...   Read More

How much do you know about Medicare Part B?

By Nicole Longo  |    July 31, 2018
In recent months, the Administration has proposed a number of changes to Medicare Part B. From the Department of Health and Human Services’ request for information, HHS Blueprint To Lower Drug...   Read More

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

By Holly Campbell  |    July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....   Read More

New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

By Lauren Neves  |    May 31, 2018
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a ...   Read More

Medicare Monday: New Xcenda white paper looks at four strengths of Part B

By Nicole Longo  |    April 30, 2018
In case you missed it, a recent white paper from Xcenda took a deeper look at how Medicare Part B reimburses for physician-administered medicines and how the program has evolved over time. The...   Read More

Medicare Monday: Moran finds Part B medicine prices are stable, not a key driver of Medicare costs

By Nicole Longo  |    March 26, 2018
Earlier this year, we examined research that shows Part B spending continues to be a small, stable share of overall Medicare spending. Today, we’re looking at the trends in Average Sales Price...   Read More

Guess what? Part B drug spending remains stable share of Medicare spending

By Nicole Longo  |    January 23, 2018
Did you know that if you look at medicines in the pipeline for previously unmet medical needs, many are new and exciting immunotherapy treatments that are physician administered? That means these...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates